Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 90.39
NVO's Cash to Debt is ranked higher than
51% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NVO: 90.39 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 3.88 Max: 90.39
Current: 90.39
0.29
90.39
Equity to Asset 0.46
NVO's Equity to Asset is ranked lower than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVO: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.46  Med: 0.66 Max: 0.73
Current: 0.46
0.46
0.73
Interest Coverage 64.58
NVO's Interest Coverage is ranked lower than
75% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 64.58 )
Ranked among companies with meaningful Interest Coverage only.
NVO' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 279.29 Max: 884.41
Current: 64.58
9.18
884.41
F-Score: 5
Z-Score: 10.83
M-Score: -2.86
WACC vs ROIC
11.45%
143.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 43.33
NVO's Operating margin (%) is ranked higher than
96% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NVO: 43.33 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 35.7 Max: 45.81
Current: 43.33
21.38
45.81
Net-margin (%) 33.93
NVO's Net-margin (%) is ranked higher than
93% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NVO: 33.93 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s Net-margin (%) Range Over the Past 10 Years
Min: 20.38  Med: 26.62 Max: 33.93
Current: 33.93
20.38
33.93
ROE (%) 88.84
NVO's ROE (%) is ranked higher than
99% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. NVO: 88.84 )
Ranked among companies with meaningful ROE (%) only.
NVO' s ROE (%) Range Over the Past 10 Years
Min: 27.38  Med: 50.43 Max: 88.84
Current: 88.84
27.38
88.84
ROA (%) 42.39
NVO's ROA (%) is ranked higher than
98% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NVO: 42.39 )
Ranked among companies with meaningful ROA (%) only.
NVO' s ROA (%) Range Over the Past 10 Years
Min: 18.46  Med: 30 Max: 42.39
Current: 42.39
18.46
42.39
ROC (Joel Greenblatt) (%) 177.27
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NVO: 177.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 43  Med: 107.33 Max: 178.92
Current: 177.27
43
178.92
Revenue Growth (3Y)(%) 12.40
NVO's Revenue Growth (3Y)(%) is ranked higher than
64% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NVO: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8  Med: 14 Max: 127.9
Current: 12.4
8
127.9
EBITDA Growth (3Y)(%) 15.30
NVO's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NVO: 15.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 9.6  Med: 16.7 Max: 130.3
Current: 15.3
9.6
130.3
EPS Growth (3Y)(%) 17.00
NVO's EPS Growth (3Y)(%) is ranked higher than
73% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NVO: 17.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 10.2  Med: 20.4 Max: 36.9
Current: 17
10.2
36.9
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S $NVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVO Guru Trades in Q1 2016

Jeremy Grantham 122,600 sh (New)
Ruane Cunniff 97,525 sh (+19.93%)
Mario Gabelli 6,225 sh (+0.24%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (-0.51%)
Jim Simons 12,775,700 sh (-0.95%)
Ken Fisher 11,178,809 sh (-2.35%)
Spiros Segalas 6,179,837 sh (-16.07%)
» More
Q2 2016

NVO Guru Trades in Q2 2016

Jim Simons 12,949,800 sh (+1.36%)
Tom Gayner 1,075,000 sh (unchged)
Spiros Segalas 6,179,837 sh (unchged)
Murray Stahl 7,740 sh (-0.60%)
Mario Gabelli 6,176 sh (-0.79%)
Ken Fisher 10,963,094 sh (-1.93%)
Ruane Cunniff 94,165 sh (-3.45%)
Jeremy Grantham 87,600 sh (-28.55%)
» More
Q3 2016

NVO Guru Trades in Q3 2016

Jim Simons 14,653,500 sh (+13.16%)
Murray Stahl 7,787 sh (+0.61%)
Spiros Segalas 7,212,304 sh (+16.71%)
Ruane Cunniff 94,165 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli Sold Out
Ken Fisher 10,910,669 sh (-0.48%)
Jeremy Grantham 61,700 sh (-29.57%)
» More
Q4 2016

NVO Guru Trades in Q4 2016

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (unchged)
Jeremy Grantham Sold Out
Spiros Segalas Sold Out
Ken Fisher 10,621,538 sh (-2.65%)
Jim Simons 13,945,900 sh (-4.83%)
Ruane Cunniff 43,687 sh (-53.61%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:GILD, NAS:CELG, NAS:BIIB, OTCPK:SHPGF, NAS:AMGN, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BMRN, OTCPK:GIKLY, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMY, NAS:TSRO, NAS:SGEN, NAS:ALKS, NAS:JAZZ » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Novo Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was launched in the United States in April 2015 and is also available in Denmark, Italy and Canada. The Company manufactures and markets pharmaceutical products and services that make a difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes & obesity care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Saudi Arabia, Algeria, Turkey, Argentina, Australia, India, Brazil, Iran and Russia.

Top Ranked Articles about Novo Nordisk A/S

Something Strange Is Going On With Oral Insulin Novo Nordisk recently abandoned program despite promising results
Something is rotten in the state of Denmark. Read more...
The PBM Empire Strikes Back Some of the largest pharmacy benefit managers are driving significant change in drug pricing
I had the privilege of speaking at the GuruFocus Conference in Omaha. The basis of my talk was finding value in health care. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.41
NVO's P/E(ttm) is ranked higher than
71% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. NVO: 16.41 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 23.58 Max: 34.41
Current: 16.41
12.13
34.41
Forward P/E 15.97
NVO's Forward P/E is ranked higher than
65% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. NVO: 15.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.41
NVO's PE(NRI) is ranked higher than
72% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. NVO: 16.41 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s PE(NRI) Range Over the Past 10 Years
Min: 12.13  Med: 23.57 Max: 34.41
Current: 16.41
12.13
34.41
Price/Owner Earnings (ttm) 18.70
NVO's Price/Owner Earnings (ttm) is ranked higher than
64% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. NVO: 18.70 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 27.92 Max: 59.57
Current: 18.7
13.81
59.57
P/B 13.84
NVO's P/B is ranked lower than
91% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. NVO: 13.84 )
Ranked among companies with meaningful P/B only.
NVO' s P/B Range Over the Past 10 Years
Min: 3.68  Med: 8.8 Max: 31.9
Current: 13.84
3.68
31.9
P/S 5.57
NVO's P/S is ranked higher than
70% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. NVO: 5.57 )
Ranked among companies with meaningful P/S only.
NVO' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 5.8 Max: 11.01
Current: 5.57
2.8
11.01
PFCF 15.56
NVO's PFCF is ranked higher than
65% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. NVO: 15.56 )
Ranked among companies with meaningful PFCF only.
NVO' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.46 Max: 47.08
Current: 15.56
12.07
47.08
POCF 12.87
NVO's POCF is ranked higher than
72% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. NVO: 12.87 )
Ranked among companies with meaningful POCF only.
NVO' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 19.82 Max: 32.54
Current: 12.87
9.91
32.54
EV-to-EBIT 12.47
NVO's EV-to-EBIT is ranked higher than
61% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. NVO: 12.47 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.7 Max: 25.7
Current: 12.47
9.2
25.7
EV-to-EBITDA 11.71
NVO's EV-to-EBITDA is ranked higher than
60% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. NVO: 11.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.1 Max: 23.6
Current: 11.71
8.2
23.6
PEG 0.95
NVO's PEG is ranked higher than
71% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. NVO: 0.95 )
Ranked among companies with meaningful PEG only.
NVO' s PEG Range Over the Past 10 Years
Min: 0.7  Med: 1.19 Max: 5.14
Current: 0.95
0.7
5.14
Shiller P/E 30.67
NVO's Shiller P/E is ranked higher than
71% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. NVO: 30.67 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s Shiller P/E Range Over the Past 10 Years
Min: 23.23  Med: 44.13 Max: 67.69
Current: 30.67
23.23
67.69
Current Ratio 1.26
NVO's Current Ratio is ranked lower than
84% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NVO: 1.26 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.14 Max: 2.45
Current: 1.26
1.26
2.45
Quick Ratio 0.96
NVO's Quick Ratio is ranked lower than
85% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. NVO: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.45 Max: 1.91
Current: 0.96
0.96
1.91
Days Inventory 288.81
NVO's Days Inventory is ranked lower than
83% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. NVO: 288.81 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 288.81
246.45
343.56
Days Sales Outstanding 66.07
NVO's Days Sales Outstanding is ranked lower than
53% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. NVO: 66.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 66.07
45.09
66.07
Days Payable 127.69
NVO's Days Payable is ranked higher than
76% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. NVO: 127.69 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 127.69
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.01
NVO's Dividend Yield is ranked higher than
89% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. NVO: 4.01 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s Dividend Yield Range Over the Past 10 Years
Min: 0.93  Med: 1.56 Max: 4.17
Current: 4.01
0.93
4.17
Dividend Payout 0.63
NVO's Dividend Payout is ranked lower than
79% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. NVO: 0.63 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.63
Current: 0.63
0.26
0.63
Dividend Growth (3y) 37.70
NVO's Dividend Growth (3y) is ranked higher than
89% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NVO: 37.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 12.7  Med: 28.9 Max: 37.7
Current: 37.7
12.7
37.7
Forward Dividend Yield 3.16
NVO's Forward Dividend Yield is ranked higher than
84% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. NVO: 3.16 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 16.01
NVO's Yield on cost (5-Year) is ranked higher than
96% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. NVO: 16.01 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.71  Med: 6.23 Max: 16.65
Current: 16.01
3.71
16.65
3-Year Average Share Buyback Ratio 1.80
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. NVO: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 1.5 Max: 8
Current: 1.8
-3.1
8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 83.93
NVO's Price/Net Current Asset Value is ranked lower than
98% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. NVO: 83.93 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.62  Med: 24.24 Max: 100.73
Current: 83.93
11.62
100.73
Price/Tangible Book 14.69
NVO's Price/Tangible Book is ranked lower than
88% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. NVO: 14.69 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 6.39 Max: 23.2
Current: 14.69
3.14
23.2
Price/Projected FCF 1.44
NVO's Price/Projected FCF is ranked higher than
79% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. NVO: 1.44 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.44  Med: 2.5 Max: 7.38
Current: 1.44
1.44
7.38
Price/DCF (Earnings Based) 0.58
NVO's Price/DCF (Earnings Based) is ranked higher than
86% of the 21 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NVO: 0.58 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.96
NVO's Price/Median PS Value is ranked higher than
50% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NVO: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 0.86 Max: 1.65
Current: 0.96
0.5
1.65
Price/Peter Lynch Fair Value 0.83
NVO's Price/Peter Lynch Fair Value is ranked higher than
78% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. NVO: 0.83 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.27  Med: 1.02 Max: 3.78
Current: 0.83
0.27
3.78
Price/Graham Number 3.28
NVO's Price/Graham Number is ranked lower than
64% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. NVO: 3.28 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.56  Med: 2.8 Max: 5.52
Current: 3.28
1.56
5.52
Earnings Yield (Greenblatt) (%) 8.06
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. NVO: 8.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 10.8
Current: 8.06
3.9
10.8
Forward Rate of Return (Yacktman) (%) 23.94
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. NVO: 23.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.5  Med: 22.7 Max: 33.5
Current: 23.94
7.5
33.5

More Statistics

Revenue (TTM) (Mil) $16,551
EPS (TTM) $ 2.22
Beta0.74
Short Percentage of Float0.14%
52-Week Range $30.89 - 57.81
Shares Outstanding (Mil)2,550.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 16,515 17,723 18,094
EPS ($) 2.24 2.39 2.55
EPS w/o NRI ($) 2.24 2.39 2.55
EPS Growth Rate
(3Y to 5Y Estimate)
6.75%
Dividends Per Share ($) 1.23 1.56 1.68
» More Articles for NVO

Headlines

Articles On GuruFocus.com
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Value Screeners Identify Top Sectors Feb 06 2017 
7 Stocks for 2017 Jan 20 2017 
Something Strange Is Going On With Oral Insulin Dec 23 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
23 Questions With Thomas Macpherson of Nintai Partners Nov 21 2016 
Graham's 4 Vital Elements Nov 10 2016 
World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 

More From Other Websites
NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class... Feb 22 2017
Canadian News Media Challenged to See the Whole Picture When Reporting on Obesity Feb 22 2017
Sanofi’s Unique Foothold in Diabetes and Cardiovascular Feb 20 2017
NOVO NORDISK SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds... Feb 17 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novo... Feb 17 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action... Feb 17 2017
9 Top Pharmaceutical Stocks to Buy for the Dividends Feb 15 2017
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And... Feb 14 2017
NVO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Novo Nordisk A/S Feb 14 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Feb 14 2017
NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Feb 13 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novo... Feb 10 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Feb 10 2017
Great Place to Work® and Fortune Name Novo Nordisk as one of the country's best workplaces for... Feb 09 2017
Top Analyst Reports for Priceline, Schwab & NextEera Energy Feb 08 2017
NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Feb 08 2017
Denmark joins race to host EU drug agency instead of London after Brexit Feb 08 2017
Novo Nordisk A/S :NVO-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017 Feb 07 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo... Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)